Reuters
"If the advisory committee and (Food and Drug Administration (news - web sites)) conclude that the benefits of this class outweigh the risks in some patient populations, then we would have to consider the implications of these new data given the unique benefits Vioxx offers," said Peter Kim, president of Merck Research Labs.
The New Jersey-based drugmaker pulled its popular pain medicines from the market in September after a clinical trial showed it doubled the risk of heart attack and stroke.
More... |
